Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on Augu... ( Company to Conduct Con...)

Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on August 5, 2008

Date:7/29/2008

Company to Conduct Conference Call and Webcast

LEXINGTON, Mass., July 29 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) will announce its third quarter 2008 financial results in a press release to be issued before market open on August 5, 2008. The Company will host a conference call and webcast to discuss these results at 9:00 AM eastern time on August 5, 2008.

The live call may be accessed by dialing 888-713-4215 from the U.S. and Canada, and 617-213-4867 from international locations. The participant passcode is 53319745. A replay of the call will be available beginning at 11:00 AM on August 5, 2008 and lasting until 12:00 AM on September 5, 2008. To access the replay, please dial 888-286-8010 from the U.S. and Canada, and 617-801-6888 from international locations, using the passcode 72001555.

The press release and the live webcast will be accessible by visiting the Investors section of the Company's website, http://www.indevus.com. An archived version of the call will be accessible at the same web address for 30 days following the live call.

About Indevus

Indevus Pharmaceuticals, Inc. is a specialty pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. The Company's approved products include SANCTURA(R) and SANCTURA XR(TM) for overactive bladder, VANTAS(R) for advanced prostate cancer, SUPPRELIN(R) LA for central precocious puberty, and DELATESTRYL(R) to treat male hypogonadism. The Indevus development pipeline contains multiple compounds within the Company's core therapeutic areas in addition to several partnered or partnera
'/>"/>

0

GOOD

Page: 1 2 3
Related biology technology :

1. Indevus Receives Approvable Letter from FDA for NEBIDO(R)
2. Indevus Announces Management Changes
3. Indevus Pharmaceuticals Scheduled to Present at Upcoming Investor Conferences
4. 125 Indevus Sales Representatives to Provide Community Service in New Orleans for Jericho Road Episcopal Housing Initiative
5. Indevus Pharmaceuticals to Present at Cowen and Company 28th Annual Health Care Conference
6. Indevus Comments on Bayer Healthcare Discontinuation of Viadur(R)
7. Indevus Receives Non-Approvable Letter From FDA for VALSTAR(TM)
8. Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
9. Indevus Announces Allergan as New Partner for SANCTURA Brand
10. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
11. VioQuest Pharmaceuticals, Inc Valuation Upgrade Review Issued By Scimitar Equity, LLC

Post Your Comments:

Indevus Pharmaceuticals to Announce Third Quarter Fiscal 2008 Financial Results on Augu...( Company to Conduct Con...)